Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 4
  1. They are contraindicated in patients with renal impairment. Bisphosphonates are most commonly used to treat patients with osteoporosis, because they are antiresorptive agents and act on osteoclasts to decrease or stop the resorption of the bone. They can pass into breast milk and, therefore, should not be used by patients who are breast-feeding. They also cause esophageal erosions and should be used with caution in patients with gastrointestinal diseases. The older generation of bisphosphonates (eg, etidronate) caused osteomalacia when used in continuous mode and in high dosages; however, the newest medications in this class (eg, alendronate, risedronate) are safer and have not been shown to cause this complication.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj